Surrozen, Inc.
SRZNSurrozen, Inc. in brief
Surrozen, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $562 M on 30 October 2026, which makes it the 12,067th largest listed company in the world and the 2,457th largest in the USA on this site. In the year to December 2025 it had sales of $3 M and a net loss of $242 M. It employs about 44 people and Craig C. Parker is its chief executive. Its largest product and service lines by sales in 2025 were Research service revenue (101%). Its shares trade under the symbol SRZN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Surrozen, Inc.
We are a biotechnology company committed to discovering and developing product candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair. Our current strategic focus is ophthalmology, where Wnt signaling plays a central role in retinal vascular integrity, barrier function, and tissue maintenance. We are located in South San Francisco, California.
Our mission is to transform the treatment of serious ophthalmic disease by fully exploiting the Wnt pathway. Building upon the seminal work of our founders and scientific advisors who discovered the Wnt gene and key regulators of the Wnt pathway, we have made breakthrough discoveries that we believe will overcome previous limitations in harnessing the potential of Wnt biology in a tissue-selective manner. These breakthroughs enable us to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling and form the foundation of our ophthalmology portfolio and research programs, which are designed to restore tissue structure and function in serious eye diseases with high unmet medical need.
From the company's annual report filed with the US SEC: read the report
Surrozen, Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- ✎Renamed Surrozen, Inc./DEFormerly Consonance-HFW Acquisition Corp..
Events of Surrozen, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,888 (Jan 2022) · #5,304 (Dec 2022) · #5,109 (Jul 2023) · #4,351 (Jan 2024) · #1,642 (Mar 2026) · #2,914 (Aug 2026) · #2,592 (Oct 2026) · #2,460 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 161.4×
- Price / book
- —
- Free cash flow yield
- -5.4%
- Net margin
- -6954.9%
- Operating margin
- -1209.5%
- Return on equity
- —
- Liabilities / assets
- 290.2%
- Revenue growth
- -67.4%
- R&D / revenue
- 843.7%
- Revenue per employee
- $79 K
- Profit per employee
- $-5.5 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3M | -67.4% | $-42M | $-242M | -6954.9% |
| Dec 2024 | $11M | — | $-26M | $-64M | -596.2% |
| Dec 2023 | — | — | $-46M | $-43M | — |
| Dec 2022 | $13M | — | $-44M | $-36M | -288.0% |
| Dec 2021 | — | — | $-54M | $-55M | — |
| Dec 2020 | — | — | $-33M | $-33M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-30M | $0M | $-30M | $-32.37 | — |
| Dec 2024 | $-18M | $0M | $-18M | $-21.67 | — |
| Dec 2023 | $-40M | $0M | $-41M | $-21.33 | — |
| Dec 2022 | $-44M | $1M | $-45M | $-15.56 | — |
| Dec 2021 | $-49M | $1M | $-50M | $-2.21 | — |
| Dec 2020 | $-29M | $1M | $-30M | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-130M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Oct 20, 20268-KCurrent reportResults of operations · Unregistered share sale
- Oct 2, 20268-KCurrent reportOther events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- May 14, 20268-KCurrent reportShareholder vote
- May 6, 202610-QQuarterly report · period to Mar 2026
- May 6, 20268-KCurrent reportResults of operations
- Apr 1, 2026DEF 14AProxy statement
- Mar 23, 202610-KAnnual report · period to Dec 2025
- Mar 23, 20268-KCurrent reportResults of operations
Official filings of Surrozen, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $3 M
- Operating income
- $-42 M
- Net income
- $-242 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $99 M
- Total liabilities
- $286 M
- Total equity
- $-188 M
As of December-2025
Top 90 institutional investors in Surrozen, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Column Group LLC | 2,951,433 | New | 15.48% | $95 M | Nov 16, 2026 |
| 2 | Boxer Capital Management, LLC | 1,360,683 | +255,000 (+23.06%) | 7.14% | $44 M | Nov 16, 2026 |
| 3 | Commodore Capital LP | 885,000 | New | 4.64% | $28 M | Nov 16, 2026 |
| 4 | Point72 Asset Management, L.P. | 806,407 | +142,135 (+21.40%) | 4.23% | $26 M | Nov 16, 2026 |
| 5 | Venrock Adviser, LLC | 632,931 | 0 (0.00%) | 3.32% | $20 M | Nov 16, 2026 |
| 6 | Balyasny Asset Management L.P. | 626,170 | +421,138 (+205.40%) | 3.29% | $20 M | Nov 16, 2026 |
| 7 | Millennium Management LLC | 596,130 | -86,949 (-12.73%) | 3.13% | $19 M | Nov 16, 2026 |
| 8 | Samlyn Capital, LLC | 504,482 | New | 2.65% | $16 M | Nov 16, 2026 |
| 9 | BlackRock, Inc. | 498,824 | +103,960 (+26.33%) | 2.62% | $16 M | Nov 13, 2026 |
| 10 | Kynam Capital Management, LP | 486,252 | New | 2.55% | $16 M | Nov 16, 2026 |
| 11 | Perceptive Advisors LLC | 439,685 | -64,300 (-12.76%) | 2.31% | $14 M | Nov 16, 2026 |
| 12 | Spruce Street Capital LP | 432,040 | 0 (0.00%) | 2.27% | $14 M | Nov 13, 2026 |
| 13 | Stempoint Capital LP | 418,527 | -184,271 (-30.57%) | 2.20% | $13 M | Nov 16, 2026 |
| 14 | RTW Investments, LP | 393,560 | New | 2.06% | $13 M | Nov 16, 2026 |
| 15 | Adage Capital Partners GP, L.L.C. | 388,653 | +300,000 (+338.40%) | 2.04% | $13 M | Nov 16, 2026 |
| 16 | Vanguard Capital Management LLC | 370,128 | -22,422 (-5.71%) | 1.94% | $12 M | Nov 13, 2026 |
| 17 | Braidwell LP | 335,206 | -55,547 (-14.22%) | 1.76% | $11 M | Nov 16, 2026 |
| 18 | Two Sigma Investments, LP | 326,345 | +255,226 (+358.87%) | 1.71% | $11 M | Nov 16, 2026 |
| 19 | Integral Health Asset Management, LLC | 325,000 | New | 1.71% | $10 M | Nov 16, 2026 |
| 20 | Kalehua Capital Management LLC | 286,092 | -484,264 (-62.86%) | 1.50% | $9 M | Nov 13, 2026 |
| 21 | Vivo Capital, LLC | 260,000 | 0 (0.00%) | 1.36% | $8 M | Nov 13, 2026 |
| 22 | UBS Group AG | 257,103 | +227,874 (+779.62%) | 1.35% | $8 M | Nov 10, 2026 |
| 23 | Geode Capital Management, LLC | 194,838 | -6,814 (-3.38%) | 1.02% | $6 M | Nov 6, 2026 |
| 24 | Fred Alger Management, LLC | 176,878 | +152,874 (+636.87%) | 0.93% | $6 M | Nov 16, 2026 |
| 25 | Janus Henderson Group Ltd. | 167,084 | — | 0.88% | $5 M | Nov 16, 2026 |
Show all 90: investors 26 to 90
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Acuta Capital Partners, LLC | 152,541 | -20,854 (-12.03%) | 0.80% | $5 M | Nov 16, 2026 |
| 27 | State Street Corp | 136,319 | +3,235 (+2.43%) | 0.72% | $4 M | Nov 12, 2026 |
| 28 | Regents Of The University Of California | 133,207 | 0 (0.00%) | 0.70% | $4 M | Oct 26, 2026 |
| 29 | Goldman Sachs Group Inc | 112,697 | -834 (-0.73%) | 0.59% | $4 M | Nov 16, 2026 |
| 30 | Euclidean Capital LLC | 87,696 | 0 (0.00%) | 0.46% | $3 M | Nov 16, 2026 |
| 31 | Northern Trust Corp | 63,414 | -195 (-0.31%) | 0.33% | $2 M | Nov 16, 2026 |
| 32 | Renaissance Technologies LLC | 63,136 | +50,762 (+410.23%) | 0.33% | $2 M | Nov 12, 2026 |
| 33 | Jump Financial, LLC | 61,084 | New | 0.32% | $2 M | Nov 13, 2026 |
| 34 | Vanguard Fiduciary Trust Co | 56,226 | -3,349 (-5.62%) | 0.29% | $2 M | Nov 13, 2026 |
| 35 | ArrowMark Colorado Holdings LLC | 55,123 | 0 (0.00%) | 0.29% | $2 M | Nov 16, 2026 |
| 36 | AQR Capital Management LLC | 52,670 | New | 0.28% | $2 M | Nov 16, 2026 |
| 37 | Vanguard Portfolio Management LLC | 51,926 | +900 (+1.76%) | 0.27% | $2 M | Nov 13, 2026 |
| 38 | Stonepine Capital Management, LLC | 44,100 | New | 0.23% | $1 M | Nov 13, 2026 |
| 39 | BNP Paribas Financial Markets | 40,852 | +32,823 (+408.81%) | 0.21% | $1 M | Nov 12, 2026 |
| 40 | Trexquant Investment LP | 39,345 | New | 0.21% | $1 M | Nov 16, 2026 |
| 41 | Citadel Advisors LLC | 35,571 | New | 0.19% | $1 M | Nov 16, 2026 |
| 42 | Man Group plc | 35,515 | New | 0.19% | $1 M | Nov 16, 2026 |
| 43 | Longaeva Partners L.P. | 32,941 | New | 0.17% | $1 M | Nov 16, 2026 |
| 44 | Price T Rowe Associates Inc /MD/ | 27,741 | 0 (0.00%) | 0.15% | $1 M | Nov 16, 2026 |
| 45 | Jane Street Group, LLC | 25,332 | New | 0.13% | $1 M | Nov 12, 2026 |
| 46 | Squarepoint Ops LLC | 22,262 | New | 0.12% | $1 M | Nov 9, 2026 |
| 47 | Informed Momentum Co LLC | 21,139 | New | 0.11% | $1 M | Nov 16, 2026 |
| 48 | Lynx1 Capital Management LP | 20,000 | New | 0.10% | $1 M | Nov 16, 2026 |
| 49 | Sphera Funds Management LTD. | 18,821 | New | 0.10% | $1 M | Nov 16, 2026 |
| 50 | Charles Schwab Investment Management Inc | 18,022 | +1,725 (+10.58%) | 0.09% | $1 M | Nov 16, 2026 |
| 51 | Bank of New York Mellon Corp | 17,119 | +1,740 (+11.31%) | 0.09% | $1 M | Nov 5, 2026 |
| 52 | Algert Global LLC | 16,430 | New | 0.09% | $1 M | Nov 17, 2026 |
| 53 | LMR Partners LLP | 13,557 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 54 | Nuveen, LLC | 12,907 | +3,127 (+31.97%) | 0.07% | $0 M | Nov 10, 2026 |
| 55 | SEI Investments Co | 12,766 | New | 0.07% | $0 M | Nov 10, 2026 |
| 56 | Jain Global LLC | 9,462 | New | 0.05% | $0 M | Nov 16, 2026 |
| 57 | Quadrature Capital Ltd | 9,007 | New | 0.05% | $0 M | Nov 13, 2026 |
| 58 | Rhumbline Advisers | 8,504 | +374 (+4.60%) | 0.04% | $0 M | Nov 10, 2026 |
| 59 | XTX Topco Ltd | 7,590 | -9,238 (-54.90%) | 0.04% | $0 M | Nov 16, 2026 |
| 60 | Bank Of America Corp /de/ | 7,406 | -23,889 (-76.33%) | 0.04% | $0 M | Nov 16, 2026 |
| 61 | Deutsche Bank AG\ | 6,431 | -871 (-11.93%) | 0.03% | $0 M | Nov 6, 2026 |
| 62 | China Universal Asset Management Co., Ltd. | 5,000 | +1,350 (+36.99%) | 0.03% | $0 M | Oct 28, 2026 |
| 63 | New York State Common Retirement Fund | 4,100 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 64 | Morgan Stanley | 3,911 | -3,240 (-45.31%) | 0.02% | $0 M | Nov 13, 2026 |
| 65 | Jpmorgan Chase & Co | 3,613 | +569 (+18.69%) | 0.02% | $0 M | Nov 12, 2026 |
| 66 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 3,582 | +201 (+5.94%) | 0.02% | $0 M | Nov 16, 2026 |
| 67 | Barclays PLC | 2,863 | +1,096 (+62.03%) | 0.01% | $0 M | Nov 6, 2026 |
| 68 | Royal Bank Of Canada | 2,711 | +2,400 (+771.70%) | 0.01% | $0 M | Nov 16, 2026 |
| 69 | Vanguard Global Advisers, LLC | 2,604 | +34 (+1.32%) | 0.01% | $0 M | Nov 13, 2026 |
| 70 | Wells Fargo & Company/mn | 2,256 | -4,442 (-66.32%) | 0.01% | $0 M | Nov 16, 2026 |
| 71 | Police & Firemen's Retirement System of New Jersey | 2,166 | 0 (0.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 72 | Global Retirement Partners, LLC | 1,393 | New | 0.01% | $0 M | Nov 10, 2026 |
| 73 | Tower Research Capital LLC (TRC) | 1,377 | +949 (+221.73%) | 0.01% | $0 M | Nov 16, 2026 |
| 74 | Strs Ohio | 1,000 | -400 (-28.57%) | 0.01% | $0 M | Oct 30, 2026 |
| 75 | Russell Investments Group, Ltd. | 802 | +215 (+36.63%) | 0.00% | $0 M | Nov 6, 2026 |
| 76 | FMR LLC | 792 | +444 (+127.59%) | 0.00% | $0 M | Nov 10, 2026 |
| 77 | Legal & General Group Plc | 715 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 78 | Ameritas Investment Partners, Inc. | 666 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 79 | Citigroup Inc | 632 | -2,823 (-81.71%) | 0.00% | $0 M | Nov 4, 2026 |
| 80 | Caitong International Asset Management Co., Ltd | 526 | +525 (+52500.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 81 | Quarry LP | 399 | New | 0.00% | $0 M | Nov 16, 2026 |
| 82 | Sterling Capital Management LLC | 241 | +215 (+826.92%) | 0.00% | $0 M | Oct 22, 2026 |
| 83 | Arax Advisory Partners | 138 | New | 0.00% | $0 M | Nov 12, 2026 |
| 84 | Allworth Financial LP | 137 | New | 0.00% | $0 M | Nov 17, 2026 |
| 85 | California State Teachers Retirement System | 101 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 86 | GAMMA Investing LLC | 62 | New | 0.00% | $0 M | Oct 8, 2026 |
| 87 | SJS Investment Consulting Inc. | 52 | New | 0.00% | $0 M | Oct 26, 2026 |
| 88 | PNC Financial Services Group, Inc. | 17 | New | 0.00% | $0 M | Nov 6, 2026 |
| 89 | US Bancorp \de\ | 14 | New | 0.00% | $0 M | Nov 5, 2026 |
| 90 | SBI Securities Co., Ltd. | 5 | New | 0.00% | $0 M | Oct 22, 2026 |
Mutual funds holding Surrozen, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 282,365 | $7 M | 2.2% | <0.01% | +189% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 161,295 | $4 M | 1.3% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 102,939 | $3 M | 0.81% | <0.01% | +60% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 80,268 | $2 M | 0.63% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 62,426 | $2 M | 0.49% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 26,513 | $1 M | 0.21% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 23,661 | $1 M | 0.19% | 0.04% | +93% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 18,022 | $0 M | 0.14% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 12,411 | $0 M | 0.10% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 11,836 | $0 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 8,584 | $0 M | 0.07% | <0.01% | +5.6% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 9,780 | $0 M | 0.08% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 7,084 | $0 M | 0.06% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 6,869 | $0 M | 0.05% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 6,143 | $0 M | 0.05% | <0.01% | +49% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 5,500 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 3,790 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 3,751 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 3,500 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 3,495 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 3,522 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 2,740 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 2,663 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 1,860 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 1,669 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,575 | $0 M | 0.01% | 0.02% | +75% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,474 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 1,611 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 1,270 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 1,270 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 1,231 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 1,149 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 1,108 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 990 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 947 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 881 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 860 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 666 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 599 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 584 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 587 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 644 | $0 M | <0.01% | <0.01% | +130% | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 638 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 561 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 364 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 225 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 198 | $0 M | <0.01% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 185 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 48 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Surrozen, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Column Group III GP, LP10% owner | Exercise of in-the-money derivativeindirect | +485,830 | $11.60 | $5.6 M | 1.39 M | Form 4 |
| filed | Tim KutzkeyDirector, 10% owner | Exercise of in-the-money derivativeindirect | +485,830 | $11.60 | $5.6 M | 1.39 M | Form 4 |
| filed | Tim KutzkeyDirector, 10% owner | Exercise of in-the-money derivativeindirect | +548,653 | $11.60 | $6.4 M | 1.57 M | Form 4 |
| filed | Column Group III GP, LP10% owner | Exercise of in-the-money derivativeindirect | +548,653 | $11.60 | $6.4 M | 1.57 M | Form 4 |
| filed | Tim KutzkeyDirector, 10% owner | Exercise of in-the-money derivativeindirect | +517,241 | $11.60 | $6.0 M | 862,068 | Form 4 |
| filed | Column Group III GP, LP10% owner | Exercise of in-the-money derivativeindirect | +517,241 | $11.60 | $6.0 M | 862,068 | Form 4 |
| filed | Chen-Ming Yu10% owner | Sellindirect | -162,500 | $21.25 | $3.5 M | 574,054 | Form 4 |
| filed | Chen-Ming Yu10% owner | Sellindirect | -162,500 | $21.25 | $3.5 M | 574,047 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Surrozen, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-5.69 reverse split in the period to ; 1-for-5.69 reverse split
Fails to deliver
- : 996 shares at $29.46
- : 494 shares at $30.35
- : 2 shares at $29.53
- : 4,981 shares at $25.48
- : 1,894 shares at $25.75
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Surrozen, Inc. scorecard#
Passes 1 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median161.4×Price to sales 161.4× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-5.4%Free cash flow is -5.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 3
- ✗Revenue grew in the newest year-67.3%Revenue down 67.3% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-32.37 vs -21.67Diluted EPS -32.37 in fiscal 2025 against -21.67 the year before (report's currency).
- ✗Net income higher than five years earlier-$242 M-$242 M in fiscal 2025 against -$33 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$242 MNet income -$242 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities9.2×Current ratio 9.22 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-6.68Z-score -6.68 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year133.3%Diluted shares up 133.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Surrozen, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 3.5−67.4%100% | 11—100% | 0−100%— | 13—100% | 0—— | — | |
| Research and development | 29+39.0%845% | 21−22.4%198% | 27−26.4%— | 37−7.9%296% | 40+56.4%— | 26—— | |
| General and administrative | 16+7.6%466% | 15−4.7%141% | 16−20.3%— | 20+39.5%159% | 14+99.6%— | 7.1—— | |
| Operating expenses | 46+25.9%1311% | 36−20.9%340% | 46−19.5%— | 57+4.5%455% | 54+65.8%— | 33—— | |
| Operating income | −42—−1211% | −26—−240% | −46—— | −44—−355% | −54—— | −33—— | |
| Interest and finance income | 3.0+78.4%86.9% | 1.7−27.6%15.9% | 2.3+200%— | 0.8+985%6.2% | 0.1−20.9%— | 0.1—— | |
| Other non-operating income (expense) | −26—−757% | −19−4955%−181% | 0.4−94.7%— | 7.6—60.4% | −0.3—— | 0—— | |
| Income before tax | −242—−6961% | −64—−597% | — | — | — | — | |
| Income tax | 0—0.0% | 0—0.0% | 0—— | 0—0.0% | 0—— | 0—— | |
| Net income including minority interests | −242—−6961% | −64—−597% | −43—— | −36—−288% | −55—— | −33—— | |
| Net income attributable to shareholders | −242—−6961% | −64—−597% | −43—— | −36—−288% | −55—— | −33—— | |
| Earnings per share, basic | -32.37—— | -21.67—— | -21.33—— | -15.56r-1.04—— | -2.21—— | — | |
| Earnings per share, diluted | -32.37—— | -21.67—— | -21.33—— | -15.56r-1.04—— | -2.21—— | — | |
| Shares, weighted average (basic) | 0.0+155%— | 0.0+45.3%— | 0.0−12.8%— | 0.0r0.0−90.6%— | 0.0—— | — | |
| Shares, weighted average (diluted) | 0.0+155%— | 0.0+45.3%— | 0.0−12.8%— | 0.0r0.0−90.6%— | 0.0r25−99.8%— | 16—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 89+158%90.4% | 35−4.1%71.3% | 36+46.0%78.2% | 25−25.4%27.6% | 33−5.4%24.1% | 35r1.0—56.4% | |
| Short-term investments | — | — | 0−100%0.0% | 51−25.6%57.2% | 69+384%50.1% | 14—22.9% | |
| Receivables | 0−100%0.0% | 2.0−5.3%4.2% | 2.2+8.8%4.7% | 2.0—2.2% | 0—0.0% | — | |
| Other current assets | 2.1+15.3%2.1% | 1.8−37.8%3.8% | 2.9−15.8%6.4% | 3.5+4.5%3.9% | 3.3+220%2.4% | 1.0—1.7% | |
| Current assets | 92+135%92.7% | 39−5.3%80.3% | 41−49.4%89.3% | 81−22.7%90.9% | 105+109%76.7% | 50r1.8—80.9% | |
| Property, plant and equipment | 0.4−23.0%0.4% | 0.6−71.5%1.2% | 2.0−45.8%4.3% | 3.6−24.3%4.1% | 4.8−17.9%3.5% | 5.8—9.4% | |
| Right-of-use (leased) assets | 6.0−23.1%6.1% | 7.8+313%16.1% | 1.9−42.2%4.1% | 3.3−28.7%3.7% | 4.6−17.5%3.3% | 5.6—9.0% | |
| Long-term investments | — | — | — | — | — | 0—0.0% | |
| Total assets | 99+104%100% | 48+5.2%100% | 46−48.5%100% | 89−34.8%100% | 137+121%100% | 62r94—100% | |
| Accounts payable | 0.7+138%0.7% | 0.3−41.7%0.6% | 0.5−20.2%1.1% | 0.7−75.8%0.7% | 2.7+53.0%2.0% | 1.8—2.9% | |
| Current liabilities | 9.9+35.7%10.1% | 7.3+2.3%15.1% | 7.1−26.6%15.5% | 9.7−28.3%10.9% | 14+86.5%9.9% | 7.3r0.3—11.7% | |
| Lease liabilities (non-current) | 5.3−19.4%5.4% | 6.6+653%13.7% | 0.9−73.9%1.9% | 3.4−39.7%3.8% | 5.6−25.2%4.1% | 7.5—12.1% | |
| Total liabilities | 286+310%290% | 70+758%144% | 8.1−39.4%17.7% | 13−51.1%15.0% | 27+86.0%20.0% | 15r3.5—23.8% | |
| Retained earnings | −527—−534% | −285—−589% | −222—−481% | −179—−200% | −143—−104% | −88r−0.4—−142% | |
| Shareholders' equity | −188—−190% | −21−156%−44.1% | 38−50.1%82.3% | 76−30.7%85.0% | 110+132%80.0% | 47r5.0—76.2% | |
| Total liabilities and equity | 99+104%100% | 48+5.2%100% | 46−48.5%100% | 89−34.8%100% | 137+121%100% | 62r94—100% | |
| Shares outstanding | 9.8+200%— | 3.3+58.1%— | 2.1+2.8%— | 2.0r30−94.3%— | 35r35+91.9%— | 18—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.5−62.8%15.4% | 1.4−24.5%13.5% | 1.9−2.3%— | 2.0−5.4%15.6% | 2.1+6.7%— | 1.9—— | |
| Share-based compensation | 3.8−6.8%110% | 4.1−5.9%38.6% | 4.4−3.2%— | 4.5+95.0%36.1% | 2.3+265%— | 0.6—— | |
| Cash from operating activities | −30—−870% | −18—−165% | −40—— | −44—−353% | −49—— | −29—— | |
| Capital expenditure | −0.1—−3.7% | −0.0—−0.2% | −0.4—— | −0.7—−5.8% | −1.3—— | −0.9—— | |
| Cash from investing activities | −0.1—−3.7% | −0.0−100%−0.2% | 52+35.0%— | 38—306% | −78—— | −15—— | |
| Shares issued | 75+366%2148% | 16—151% | 0—— | 0−100%0.0% | 124—— | 0—— | |
| Shares bought back | — | — | 0—— | −2.6—−20.9% | 0—— | — | |
| Cash from financing activities | 85+426%2446% | 16+5761%152% | 0.3—— | −2.6−102%−20.5% | 125+149%— | 50—— | |
| Change in cash | 55—1573% | −1.5−113%−13.9% | 12—— | −8.4—−67.2% | −1.9−132%— | 5.9—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 11+192%100% | 0−100%— | 5.0+409%100% | 5.0+409%100% | 0.5*−19.4%100% | 1.0−90.2%100% | 1.0—100% | 1.0—100% | 0.7*—100% | 10—100% | 0—— | 0—— | 0*—— | |
| Research and development | 38+46.3%358% | 11+39.4%— | 8.5+40.4%170% | 9.3+42.2%187% | 9.0*+68.1%1703% | 7.8+49.5%791% | 6.0+13.3%615% | 6.6+25.0%667% | 5.4*−12.2%817% | 5.2—52.0% | 5.3—— | 5.2—— | 6.1*—— | |
| General and administrative | 24+50.7%228% | 6.8+66.2%— | 6.9+74.0%138% | 6.1+54.1%123% | 4.2*+7.2%791% | 4.1+14.7%416% | 4.0+6.6%403% | 4.0+2.4%404% | 3.9*+8.6%595% | 3.6—35.7% | 3.7—— | 3.9—— | 3.6*—— | |
| Operating expenses | 62+48.0%585% | 18+48.7%— | 15+53.7%307% | 15+46.7%309% | 13*+42.4%2494% | 12+35.4%1207% | 10+10.5%1017% | 11+15.4%1072% | 9.2*−4.9%1412% | 8.8—87.7% | 9.0—— | 9.1—— | 9.7*—— | |
| Operating income | −51—−485% | −18—— | −10—−207% | −10—−209% | −13*—−2394% | −11−984%−1107% | −9.0—−917% | −9.6—−972% | −8.6*—−1312% | 1.2—12.3% | −9.0—— | −9.1—— | −9.7*—— | |
| Interest and finance income | 3.6+35.5%33.7% | 0.9+0.1%— | 0.9−8.5%18.8% | 0.9+208%18.2% | 0.8*+104%149% | 0.9+111%92.7% | 1.0+109%104% | 0.3−23.1%30.1% | 0.4*−24.0%59.1% | 0.4—4.3% | 0.5—— | 0.4—— | 0.5*—— | |
| Other non-operating income (expense) | −119−988%−1135% | −39—— | 20+25.5%407% | −41−208%−822% | −60*—−11287% | −21—−2128% | 16+339%1650% | 38—3864% | −20*−6668%−3028% | −3.1—−31.0% | 3.7—— | −0.1—— | 0.3*—— | |
| Income tax | 0—0.0% | 0—— | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Net income including minority interests | −390—−3706% | −130—— | 50+26.2%1004% | −128—−2550% | −183*—−34689% | −72—−7288% | 40—4043% | −27—−2744% | −28*—−4281% | −1.4—−14.3% | −25—— | −8.8—— | −8.9*—— | |
| Net income attributable to shareholders | −390—−3706% | −130—— | 50+26.2%1004% | −128—−2550% | −183*—−34689% | −72—−7288% | 40—4043% | −27—−2744% | −28*—−4281% | −1.4—−14.3% | −25—— | −8.8—— | −8.9*—— | |
| Earnings per share, basic | — | -11.02—— | 2.75+7.8%— | -11.65—— | — | -8.36—— | 2.55—— | -7.43—— | — | -0.44—— | -7.99—— | -4.24—— | — | |
| Earnings per share, diluted | — | -11.02—— | -0.41−116%— | -11.65—— | — | -8.36—— | 2.55—— | -7.43—— | — | -0.44—— | -7.99—— | -4.24—— | — | |
| Shares, weighted average (basic) | 0.0+37.4%— | 0.0+37.4%— | 12+36.6%— | 0.0+202%— | — | 0.0+166%— | 8.5r0.0+270014%— | 0.0+74.2%— | — | 0.0r3.2—— | 0.0r3.2—— | 0.0—— | — | |
| Shares, weighted average (diluted) | 0.0+37.4%— | 0.0+37.4%— | 23+171%— | 0.0+202%— | — | 0.0+166%— | 8.5r0.0+270014%— | 0.0+74.2%— | — | 0.0r3.2—— | 0.0r3.2—— | 0.0—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 100—92.0% | 100+23.4%92.0% | 102+12.9%88.3% | 107+5.2%88.6% | 89+158%90.4% | 81+162%86.5% | 90+139%88.0% | 102+272%88.5% | 35−4.1%71.3% | 31—64.6% | 38—83.8% | 27—74.3% | 36—78.2% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Receivables | — | — | 5.0+116%4.3% | 5.0+135%4.1% | 0−100%0.0% | 2.3−81.0%2.5% | 2.3+9.7%2.3% | 2.1+0.1%1.9% | 2.0−5.3%4.2% | 12—25.4% | 2.1—4.7% | 2.1—5.8% | 2.2—4.7% | |
| Other current assets | 2.5—2.3% | 2.5+29.5%2.3% | 2.4+85.0%2.0% | 2.0+17.6%1.7% | 2.1+15.3%2.1% | 2.0−5.8%2.1% | 1.3−27.5%1.2% | 1.7−33.2%1.5% | 1.8−37.8%3.8% | 2.1—4.3% | 1.8—3.9% | 2.6—7.1% | 2.9—6.4% | |
| Current assets | 103—94.4% | 103+19.8%94.4% | 109+16.1%94.6% | 114+7.5%94.4% | 92+135%92.7% | 86+89.6%91.3% | 94+126%91.8% | 106+231%92.3% | 39−5.3%80.3% | 45—94.3% | 42—92.4% | 32—87.2% | 41—89.3% | |
| Property, plant and equipment | 0.4—0.4% | 0.4+211%0.4% | 0.5+159%0.4% | 0.5+65.4%0.4% | 0.4−23.0%0.4% | 0.1−83.8%0.1% | 0.2−85.3%0.2% | 0.3−81.4%0.3% | 0.6−71.5%1.2% | 0.9—1.8% | 1.2—2.7% | 1.6—4.3% | 2.0—4.3% | |
| Right-of-use (leased) assets | 4.7—4.3% | 4.7−27.9%4.3% | 5.1−26.1%4.4% | 5.6−24.5%4.6% | 6.0−23.1%6.1% | 6.5+689%6.9% | 6.9+487%6.7% | 7.4+380%6.4% | 7.8+313%16.1% | 0.8—1.7% | 1.2—2.6% | 1.5—4.2% | 1.9—4.1% | |
| Total assets | 109—100% | 109+15.9%100% | 116+12.6%100% | 121+5.1%100% | 99+104%100% | 94+95.9%100% | 103+128%100% | 115+213%100% | 48+5.2%100% | 48—100% | 45—100% | 37—100% | 46—100% | |
| Accounts payable | 0.7—0.6% | 0.7+21.2%0.6% | 1.1+203%0.9% | 0.9+194%0.7% | 0.7+138%0.7% | 0.5+94.9%0.6% | 0.4+105%0.3% | 0.3+131%0.3% | 0.3−41.7%0.6% | 0.3—0.6% | 0.2—0.4% | 0.1—0.4% | 0.5—1.1% | |
| Current liabilities | 14—12.5% | 14+109%12.5% | 9.0+56.9%7.8% | 9.6−9.6%7.9% | 9.9+35.7%10.1% | 6.5+6.7%6.9% | 5.7−4.0%5.6% | 11+71.3%9.2% | 7.3+2.3%15.1% | 6.1—12.8% | 6.0—13.3% | 6.2—16.8% | 7.1—15.5% | |
| Lease liabilities (non-current) | 3.8—3.5% | 3.8−35.1%3.5% | 4.3−31.5%3.7% | 4.9−28.4%4.0% | 5.3−19.4%5.4% | 5.8—6.2% | 6.3—6.2% | 6.8+2939%5.9% | 6.6+653%13.7% | 0—0.0% | 0—0.0% | 0.2—0.6% | 0.9—1.9% | |
| Total liabilities | 445—408% | 445+278%408% | 334+501%289% | 399+265%330% | 286+310%290% | 118+178%125% | 56+42.5%54.1% | 109+1559%95.1% | 70+758%144% | 42—88.2% | 39—86.6% | 6.6—17.9% | 8.1—17.7% | |
| Retained earnings | −734—−673% | −734—−673% | −605—−523% | −655—−542% | −527—−534% | −344—−366% | −272—−265% | −312—−272% | −285—−589% | −257—−536% | −256—−568% | −231—−628% | −222—−481% | |
| Shareholders' equity | −336—−308% | −336—−308% | −219−564%−189% | −278−5002%−230% | −188—−190% | −24−515%−25.0% | 47+677%45.9% | 5.7−81.2%4.9% | −21−156%−44.1% | 5.7—11.8% | 6.1—13.4% | 30—82.1% | 38—82.3% | |
| Total liabilities and equity | 109—100% | 109+15.9%100% | 116+12.6%100% | 121+5.1%100% | 99+104%100% | 94+95.9%100% | 103+128%100% | 115+213%100% | 48+5.2%100% | 48—100% | 45—100% | 37—100% | 46—100% | |
| Shares outstanding | 12—— | 12+40.3%— | 12+37.2%— | 11+35.3%— | 9.8+200%— | 8.6+164%— | 8.6+167%— | 8.5+303%— | 3.3+58.1%— | 3.3—— | 3.2—— | 2.1—— | 2.1—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.2−74.0%2.0% | 0.1*−16.4%— | 0.1*−62.8%1.0% | 0.1−77.9%1.3% | 0.0*−86.0%8.5% | 0.1*−82.2%6.2% | 0.1*−64.5%13.9% | 0.3−25.0%29.9% | 0.3*−28.6%49.2% | 0.3*—3.4% | 0.4*—— | 0.4—— | 0.5*—— | |
| Share-based compensation | 8.9+139%84.8% | 2.9*+191%— | 2.9*+191%57.9% | 2.1+152%42.1% | 1.0*+11.3%190% | 1.0*−3.3%102% | 1.0*−13.2%101% | 0.8−19.0%84.8% | 0.9*−23.2%137% | 1.0*—10.4% | 1.1*—— | 1.0—— | 1.2*—— | |
| Cash from operating activities | −31—−290% | −4.8*—— | −7.4*—−148% | −12—−250% | −5.8*−267%−1101% | −9.0*—−920% | −6.1*—−622% | −9.3—−944% | 3.5*—531% | −6.8*—−67.5% | −5.6*—— | −8.7—— | −7.3*—— | |
| Capital expenditure | −0.2—−2.1% | −0.0*—— | −0.0*—−0.4% | −0.1—−2.4% | −0.1*—−11.2% | −0.0*—−2.4% | −0.0*—−1.8% | −0.0—−2.7% | −0.0*—−2.9% | 0*—0.0% | 0*—— | −0.0—— | 0*—— | |
| Cash from investing activities | −0.2—−2.1% | −0.0*—— | −0.0*—−0.4% | −0.1—−2.4% | −0.1*—−11.2% | −0.0*—−2.4% | −0.0*—−1.8% | −0.0—−2.7% | −0.0*−100%−2.9% | 0*—0.0% | 0*—— | −0.0—— | 9.5*—— | |
| Shares issued | 3.5−95.1%33.3% | 0*—— | 0*—0.0% | 0−100%0.0% | 3.5*—663% | 0*—0.0% | −5.2*−132%−527% | 76—7771% | 0*—0.0% | −0.0*—−0.0% | 16*—— | 0—— | 0*—— | |
| Cash from financing activities | 50−30.3%472% | 3.2*+35111%— | 2.5*—50.2% | 30−60.4%606% | 14*+15044%2610% | 0.0*—0.9% | −5.1*−132%−521% | 76—7771% | 0.1*−35.5%13.9% | −0.0*—−0.0% | 16*—— | 0—— | 0.1*—— | |
| Change in cash | 19−62.3%180% | −1.7*—— | −4.9*—−98.5% | 18−73.7%353% | 7.9*+123%1498% | −9.1*—−921% | −11*−207%−1145% | 67—6824% | 3.6*+52.5%542% | −6.8*—−67.5% | 10*—— | −8.8—— | 2.3*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Surrozen, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Research service revenue$4 M101%+400%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Surrozen, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Craig Parker | $2.8 M | $4.8 M | $1.4 M | $240 |
| 2024Craig Parker | $1.5 M | $1.9 M | $927 K | $153 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Surrozen, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 4 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 3 · Shareholder vote 3 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Unregistered share saleResults announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersResults announced | 8-K | |
| Agreement ended | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Surrozen, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $130 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Scientist II, Protein SciencesMedical Scientists, Except Epidemiologists | 1 | $130 K |
Where: South San Francisco, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $130 K | 1 |
| FY2024 | 1 | 1 | $143 K | 1 |
| FY2023 | 2 | 2 | $111 K | 2 |
| FY2022 | 4 | 4 | $121 K | 4 |
| FY2021 | 4 | 4 | $103 K | 4 |
| FY2020 | 2 | 2 | $64 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Surrozen, Inc.
Discuss Surrozen, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 9 November 2026automatic update · Nov 9, 2026
Surrozen, Inc. announced results on 9 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $130 million.
- Mutual funds: 48 funds hold $22 millionautomatic update · Jul 31, 2026
48 mutual funds in 1 country hold shares of Surrozen, Inc. worth $22 million, about 6.9% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 43 funds added shares and 1 sold; on balance they bought $16 million. Share splits are not counted as trading.
How Surrozen, Inc. compares in Biotechnology
- Market cap$562 M · higher than 60% of 726
- Revenue$3 M · higher than 33% of 647
- Revenue growth-67.3% · higher than 12% of 438
- Price / sales161.4× · lower than 7% of 339
- FCF yield-5.4% · higher than 71% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Surrozen, Inc.🇺🇸 | $562 M | — | — | -67.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- MapLight Therapeutics, Inc.$558 M
- Zhejiang Orient Gene Biotech Co., Ltd$553 M
- Oneness Biotech Co., Ltd.$577 M
- Arvinas, Inc.$544 M
- Entera Bio Ltd.$543 M
- Shattuck Labs, Inc.$588 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 1, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Surrozen, Inc.? Verify and update this profile — free
Show Surrozen, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.